Experimental drug ‘reduces brain amyloid burden’ in early Alzheimer’s disease
Moderately less decline seen in cognition and function at 18 months with lecanemab versus placebo, trial shows
For patients with early Alzheimer’s disease, lecanemab reduced markers of amyloid and resulted in moderately less decline in cognition and function at 18 months, according to a study published in the New England Journal of Medicine.
Dr Christopher H Van Dyck, from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted an 18-month phase 3 trial involving adults aged 50-90 with early Alzheimer’s disease with evidence of amyloid on PET or CSF testing.
Participants were randomly assigned to receive IV lecanemab or placebo (898 and 897, respectively).
The researchers found that in both groups, the mean Clinical Dementia Rating-Sum of Boxes was approximately 3.2.
